Support des patrons de conception dans les outils UML

Les outils UML intégrant le support de l utilisation des patrons de conception doivent permettent une mise en œuvre correcte des solutions de patrons, sans remettre en cause la cohérence des modèles UML. Ils doivent permettre aussi de vérifier que les solutions des patrons appliqués résolvent réellement les problèmes de conception auxquels ces solutions sont destinées et que les contextes d application ne contrarient pas les principes de conception que ces solutions utilisent pour résoudre les problèmes. Nous nous intéressons dans cette thèse aux aspects solution et problème des patrons de conception. Nous proposons un ensemble de contraintes et de transformations permettant : i) une intégration correcte et cohérente des solutions de patrons dans les modèles UML. ii) spécifier la partie des problèmes de conception liés au couplage des patrons de conception GOF. Nous utilisons l ensemble de contraintes et de transformations obtenues sous forme d une extension au standard UML.PARIS-BIUSJ-Thèses (751052125) / SudocPARIS-BIUSJ-Mathématiques rech (751052111) / SudocSudocFranceF

Improving Pattern Support in UML CASE tools

International audienc

Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients The ENDORSE Global Survey

Limited data are available regarding the risk for venous thromboembolism (VIE) and VIE prophylaxis use in hospitalised medically ill patients. We analysed data from the global ENDORSE survey to evaluate VTE risk and prophylaxis use in this population according to diagnosis, baseline characteristics, and country. Data on patient characteristics, VIE risk, and prophylaxis use were abstracted from hospital charts. VTE risk and prophylaxis use were evaluated according to the 2004 American College of Chest Physicians (ACCP) guidelines. Multivariable analysis was performed to identify factors associated with use of ACCP-recommended prophylaxis. Data were evaluated for 37,356 hospitalised medical patients across 32 countries. VIE risk varied according to medical diagnosis, from 31.2% of patients with gastrointestinal/hepatobiliary diseases to 100% of patients with acute heart failure, active noninfectious respiratory disease, or pulmonary infection (global rate, 41.5%). Among those at risk for VTE, ACCP-recommended prophylaxis was used in 24.4% haemorrhagic stroke patients and 40-45% of cardiopulmonary disease patients (global rate, 39.5%). Large differences in prophylaxis use were observed among countries. Markers of disease severity, including central venous catheters, mechanical ventilation, and admission to intensive care units, were strongly associated with use of ACCP-recommended prophylaxis. In conclusion, VIE risk varies according to medical diagnosis. Less than 40% of at-risk hospitalised medical patients receive ACCP-recommended prophylaxis. Prophylaxis use appears to be associated with disease severity rather than medical diagnosis. These data support the necessity to improve implementation of available guidelines for evaluating VIE risk and providing prophylaxis to hospitalised medical patients

Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey) Findings in Surgical Patients

Objective: To evaluate venous thromboembolism (VTE) risk in patients who underwent a major operation, including the use of, and factors influencing, American College of Chest Physicians-recommended types of VTE prophylaxis